About: Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study
Creator	De Clercq, Erik Li, Guangdi Zhang, Min Xie, Qing Mao, Qing Shang, Jia Xu, Yun Ding, Hai Fan, Wenzhou Jiang, Yongfang Luo, Kaizhong Pan, Chen Peng, Yanzhong Wang, Guiqiang Yin, Zhibiao Zhang, Minxiang Guozhong Gong, · Mahmoud, · Pourkarim, Reza Vidaurre, · Xinqiang, ·
Source	PMC
abstract	BACKGROUND: As an important anti-HBV drug, pegylated interferon α (PegIFNα) offers promising clinical efficacy, but biomarkers that accurately forecast treatment responses are yet to be elucidated. Here, we evaluated whether HBV RNA could act as an early monitor of pegylated interferon responses. METHODS: We analyzed a phase 3, multicenter, randomized cohort of 727 HBeAg-positive non-cirrhotic patients receiving a 48-week treatment of PegIFNα-2a or PegIFNα-2b and a 24-week treatment-free follow-up. Serum levels of HBV RNA, HBV DNA, HBeAg, and HBsAg were measured at weeks 0, 12, 24, 48, and 72. RESULTS: HBeAg seroconversion and HBsAg loss at week 72 were observed in 217 (29.8%) and 21 (2.9%) patients, respectively. During the 48-week treatment, HBV RNA decreased more rapidly than HBV DNA and HBsAg, but HBV RNA and HBeAg shared similar dynamics with positive correlations. Multivariate regression analyses consistently revealed the significance of HBV RNA at weeks 0, 12, 24, and 48 to monitor HBeAg seroconversion but not HBsAg loss. Although baseline HBV RNA only showed a modest AUC performance, HBV RNA with a significant increase of AUC at week 12 outperformed other HBV biomarkers to forecast HBeAg seroconversion (p value < 0.05). HBV RNA ≤ 1000 copies/mL was an optimized cutoff at week 12 that offered better prediction than other HBV biomarkers. This optimized cutoff plus patient age, HBV genotype B, and HBeAg offered a strong estimation of HBeAg seroconversion (accuracy 95.2%, true negative rate 99.8%). CONCLUSION: HBV RNA at week 12 is an effective monitor of HBeAg seroconversion in HBeAg-positive patients treated with pegylated interferons. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12072-020-10015-3) contains supplementary material, which is available to authorized users.
has issue date	2020-02-25(xsd:dateTime)
bibo:doi	10.1007/s12072-020-10015-3
bibo:pmid	32100261
has license	cc-by
sha1sum (hex)	7d6cc862605fbb3a906c07870b27c66552e1fe93
schema:url	https://doi.org/10.1007/s12072-020-10015-3
resource representing a document's title	Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study
has PubMed Central identifier	PMC7136184
has PubMed identifier	32100261
schema:publication	Hepatol Int
resource representing a document's body	covid:7d6cc862605fbb3a906c07870b27c66552e1fe93#body_text
is schema:about of	named entity 'estimation' named entity 'receiving' named entity 'Background' named entity 'measured' named entity 'monitor' named entity 'copies' named entity 'true negative rate' named entity 'RNA' named entity 'HBV' named entity 'interferons' named entity 'REGRESSION ANALYSES' named entity 'RNA' named entity 'TREATMENT' named entity '727' named entity 'BASELINE' named entity 'CUTOFF' named entity 'FOLLOW-UP' named entity 'LEVELS' named entity '217' named entity 'TREATED WITH' named entity 'HBsAg' named entity 'Although' named entity '727' named entity 'biomarkers' named entity 'pegylated interferon' named entity 'Serum' named entity 'HBV' named entity 'genotype' named entity 'multicenter' named entity 'HBV' named entity 'responses' named entity 'rapidly' named entity 'patients' named entity 'HBeAg' named entity 'HBeAg' named entity 'HBV' named entity 'biomarkers' named entity 'seroconversion' named entity 'HBsAg' named entity 'HBV' named entity 'seroconversion' named entity 'pegylated interferon' named entity 'HBeAg' named entity 'HBV' named entity 'HBV' named entity 'seroconversion' named entity 'RNA' named entity 'levels' named entity 'polyadenylated' named entity 'cDNA' named entity 'HBV' named entity 'seroconversion' named entity 'Kolmogorov-Smirnov' named entity 'seroconversion' named entity 'HBV' named entity 'HBV' named entity 'nucleic acid' named entity 'HBV' named entity 'RNA' named entity 'RNA' named entity 'RNA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software